Growth HormoneCJC-1295 DAC
Long-Acting Growth Hormone-Releasing Hormone (GHRH) Analogue
Long-acting GHRH analogue investigated in growth-hormone signalling.
EU Delivery: 2–4 Business Days
About this peptide
CJC-1295 DAC is a long-acting GHRH analogue engineered with a drug-affinity complex that binds serum albumin, extending its half-life to roughly a week and producing a sustained rise in GH and IGF-1.
By continuously stimulating the pituitary GHRH receptor, CJC-1295 DAC lifts the entire growth-hormone axis rather than producing a single pulse. IGF-1 climbs steadily and remains elevated between doses, driving durable improvements in body composition, recovery and tissue quality.
The result is a leaner physique, faster healing, thicker skin, denser bone and higher day-to-day vitality. It pairs powerfully with Ipamorelin, which converts the elevated baseline into strong pulses.
One or two weekly injections are enough to keep the axis fully engaged.
Research profile
Sustained GH and IGF-1 elevation for up to a week per dose.
Drives fat loss and lean tissue gain over months.
Accelerates repair of muscle, connective tissue and skin.
One or two injections per week.
Research areas
- Sustained elevation of GH and IGF-1
- Substantial fat loss and lean muscle gain
- Denser bone and stronger connective tissue
- Improved sleep, skin and vitality
- Convenient weekly dosing
- Synergises with Ipamorelin for amplified GH pulses
Specifications
- Class
- GHRH analogue with DAC
- Presentation
- 5 mg lyophilised vial
- Analytical
- Batch tested · HPLC verified
- Storage
- 2–8 °C, protect from light
Verified customer reviews
No reviews yet. Reviews come only from customers with a delivered order.
For research use only. Not intended for human or veterinary therapeutic use.
